Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 µM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.
酪氨酸-DNA磷酸二酯酶1(Tdp1)是人类中重要的DNA修复酶,是开发新的化疗增敏剂的当前和有希望的抑制靶点,因为它能够去除由拓扑异构酶1(Top1)毒素(如托泊替康和伊立曲汀)引起的DNA损伤。在这里,我们报告了我们对合成和表征结合芳基香豆素(新黄酮类)和单萜类基团的新Tdp1抑制剂的工作。我们的结果显示,它们是有效的Tdp1抑制剂,其IC50值在亚微摮摩尔范围内。对小鼠进行的体内实验显示,化合物3ba(IC50值为0.62 µM)显著增加了托泊替康对Krebs-2腹水瘤模型的抗肿瘤效果。我们的结果进一步加强了Tdp1是一个可药用的靶点,并有潜力作为与Top1毒素联合使用的临床有效的辅助治疗方法的论点。